Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata a large retrospective study on 142 patients with a self-controlled design

Journal of the European Academy of Dermatology and Venereology, 04/05/2012

Topical immunotherapy with diphenylcyclopropenone (DCP) of patients with alopecia areata (AA) is rather effective and mostly well tolerated. The extent of hair loss before therapy is the main predictor for the therapeutic success of DCP. However, DCP therapy is associated with a high degree of relapse of which patients should be well informed.

Print Article Summary Cat 2 CME Report